EZH2 and head and neck squamous cell carcinoma: Zhou et al. [45] studied the effect of EZH2 inhibitors, including GSK126 and EPZ6438, on the antigen presentation in head and neck squamous cell carcinoma (HNSCC) cell lines of humans and mice.